These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34541922)

  • 41. Impact of drug interactions with direct oral anticoagulants on mortality in elderly with atrial fibrillation during the COVID-19 pandemic.
    Ersoy İ; Ersoy P
    Med Clin (Engl Ed); 2023 Jan; 160(2):71-77. PubMed ID: 36686566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study.
    Hsu JY; Liu PP; Liu AB; Lin SM; Huang HK; Loh CH
    J Am Heart Assoc; 2021 Feb; 10(5):e016437. PubMed ID: 33586465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
    Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults.
    Fohtung RB; Novak E; Rich MW
    J Am Geriatr Soc; 2017 Nov; 65(11):2405-2412. PubMed ID: 28832920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Komatsubara I; Kusachi S
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):118-126. PubMed ID: 28170360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Plitt A; Ruff CT; Giugliano RP
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1019-34. PubMed ID: 27637305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation.
    Yao X; Inselman JW; Ross JS; Izem R; Graham DJ; Martin DB; Thompson AM; Ross Southworth M; Siontis KC; Ngufor CG; Nath KA; Desai NR; Nallamothu BK; Saran R; Shah ND; Noseworthy PA
    Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e006515. PubMed ID: 33012172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
    Zhu J; Alexander GC; Nazarian S; Segal JB; Wu AW
    Pharmacotherapy; 2018 Sep; 38(9):907-920. PubMed ID: 29920705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry.
    Liu C; Du X; Jiang C; He L; Chang SS; Guo XY; Yu RH; Long DY; Bai R; Liu N; Sang CH; Jiang CX; Dong JZ; Lip GYH; Ma CS
    Med Sci Monit; 2019 Apr; 25():2649-2657. PubMed ID: 30971681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthcare Utilization and Expenditures in Working-Age Adults with Atrial Fibrillation: The Effect of Switching from Warfarin to Non-Vitamin K Oral Anticoagulants.
    Feng X; Sambamoorthi U; Innes K; LeMasters T; Castelli G; Dwibedi N; Tan X
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):513-520. PubMed ID: 30144015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction.
    Lee KH; Park HW; Cho JG; Yoon NS; Kim SS; Kim MR; Kim MC; Cho KH; Kim HK; Kim CH; Kim KH; Jun SJ; Kim WJ; Lee KJ; Jeong HC; Cho JY; Park KH; Sim Ds; Yoon HJ; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC
    Europace; 2015 Oct; 17 Suppl 2():ii69-75. PubMed ID: 26842118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study.
    Søgaard M; Skjøth F; Jensen M; Kjældgaard JN; Lip GYH; Larsen TB; Nielsen PB
    J Am Heart Assoc; 2019 Jun; 8(11):e011358. PubMed ID: 31138001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.